Respiratory distress syndrome (RDS) impacts a high proportion of preterm neonates,
resulting in significant morbidity and mortality. Advances in pharmacotherapy, specifically …

Two main strategies are available for the prevention of neonatal respiratory distress
syndrome (RDS) in cases of preterm delivery: antenatal administration of hormones that …

Surfactant substitution has been a major breakthrough in the treatment of neonatal
respiratory distress syndrome (RDS), primarily caused by a lack of pulmonary surfactant; it …

The introduction of exogenous surfactant in the 1980s has resulted in an improved survival
of very preterm infants with respiratory distress syndrome. Randomized controlled trials …

Surfactant replacement in preterm infants with respiratory distress syndrome (RDS) has
been a major therapeutic breakthrough and the most intensively studied intervention in …

Respiratory distress syndrome (RDS) is seen primarily in the preterm neonate and is due
mostly to pulmonary surfactant deficiency. Lung atelectasis leads to ventilation-perfusion …

Surfactant is now standard of care for infants with respiratory distress syndrome. Surfactant
treatments are effective because of complex metabolic interactions between surfactant and …

Surfactant treatments have been the standard of care for infants who have respiratory
distress syndrome (RDS) ever since the United States Food and Drug Administration …

A randomized, placebo-controlled trial of human surfactant given intratracheally at birth
(prophylactic) versus rescue admisistration after the onset of severe respiratory distress …

OBJECTIVE: Our objective was to test the hypothesis that prenatal maternal corticosteroids
would improve the subsequent response of infants to surfactant treatments. STUDY …